Madrigal Shows Confidence As It Awaits FDA’s March Decision On Resmetirom

With a 14 March FDA action date and no advisory panel scheduled, Madrigal is looking ahead to resmetirom becoming the first approved NASH therapy, following stumbles by competitors.